4C LABS Ltd. (the “Company” or “4C LABS Ltd”) is pleased to announce that it has entered into a strategic distribution agreement with MAMEDICA (“Mamedica”), a leading medical cannabis clinic and pharmacy based in London.
Mamedica and 4C LABS expect to commercialise medical cannabis products under The Green Organic Dutchman brand & other to-be-announced brands in the UK, commencing later this year. Pursuant to the agreement, 4C LABS will supply Mamedica with curated, EU GMP Medical Cannabis products which will be available through Mamedica’s Dispensary.
Mamedica is one of the fastest-growing clinics in the UK’s emerging medical cannabis market. Testament to this, the service has witnessed a 400% increase in patient numbers through 2023. Looking to the future, Mamedica expects that this progression will continue over the coming years and aims to become one of the largest clinic and pharmacy operators in the UK.
Mamedica has identified several factors that contribute to customer dissatisfaction, including product quality, cost, service, and supply chain challenges. Recognising the pivotal role of customer experience in driving market growth, Mamedica is taking proactive steps to address these concerns. Therefore, in a progressive move to provide customers with the world’s best EU GMP products, Mamedica’s partnership with 4C LABS offers competitive price points and a guaranteed excellent customer service experience.
4C LABS product lines are composed of products from The Green Organic Dutchman, a premier, certified organic grower of medical cannabis in living soil, this comes alongside other to-be-announced brands. The Green Organic Dutchman recently received EU GMP certification for its greenhouse facilities located in Ancaster, Ontario and Canada. This certification permits the company to export specific medical cannabis products to numerous global markets, including the UK.
The growing company believes that there is strong demand for quality amongst consumers of Canadian cannabis products in the UK & Channel Islands’ burgeoning medical cannabis markets. The team at 4C LABS anticipate the market to expand over the next five years, mirroring previously legalized medical markets elsewhere. This agreement is expected to help establish a leading position for 4C LABS in the UK & Channel Islands medical cannabis markets.
Patients in the UK will benefit from the new agreement between Mamedica and 4C LABS as they will now have access to products, market proven in Canada the world’s most sophisticated cannabis market. The Green Organic Dutchman products mark the first of a number of new products being introduced to the UK & Channel Islands. These products will be launched in September 2023 and made with unbeatable quality and compelling price points.
Greg Dobbin, 4C LABS’ CEO, stated: “We are extremely pleased to be able to offer The Green Organic Dutchman products to Mamedica patients. Mamedica is a best-in-class company whose focus on patient satisfaction will ensure strong future growth.”
Jon Robson, Mamedica’s CEO and founderstated: “We are pleased to announce our partnership with 4C LABS to introduce their esteemed portfolio of Canadian medical cannabis products to the UK market. We eagerly anticipate the introduction of 4C LABS’ highly regarded EU GMP products and we are excited to collaborate with industry experts such as Greg and James.”
